Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:52:20.283Z.
Calculation as of: 2026-10-06T18:52:20.283Z.
Quote observation: 2026-10-06T18:37:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ceb9d7bb150905ac81611c4688aa1bd793b2f4eb464ba4dc05e218b0340a6d90
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$1.49M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NewcelX Ltd. (NCEL) | $1.37M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.35M | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.34M | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.35M | N/A | N/A | N/A | N/A |
| INVO Fertility, Inc. (IVF)vs › | $1.43M | N/A | N/A | N/A | N/A |
| NEXGEL, Inc. (NXGL)vs › | $1.44M | N/A | N/A | N/A | N/A |
| Curis, Inc. (CRIS)vs › | $1.47M | N/A | 0.69% | 0.69% | 0.69% |
| PMGC Holdings Inc. (ELAB)vs › | $1.46M | N/A | N/A | N/A | N/A |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.49M | N/A | N/A | N/A | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.14M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
